Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Silexion Therapeutics ( (SLXN) ) has shared an announcement.
On March 24, 2026, Silexion Therapeutics announced that the Israeli Ministry of Health had approved initiation of a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, following strong anti-tumor activity in multiple preclinical models and completion of toxicology studies. The clearance marks Silexion’s transition into a clinical-stage biotech targeting KRAS-driven cancers and supports its strategy to develop SIL204 as a broadly applicable RNAi therapy, with first human dosing expected in the second quarter of 2026 and plans to expand into additional indications and European jurisdictions.
SIL204 is engineered to silence a wide range of KRAS mutations, which occur in more than 90% of pancreatic cancers and are considered among oncology’s most challenging targets. The regulatory milestone, underpinned by supportive interactions with health authorities and prior safety data from a predecessor compound, strengthens Silexion’s position in the precision oncology landscape and has implications for patients, investors, and partners looking for new options in high unmet-need gastrointestinal and lung cancers.
The most recent analyst rating on (SLXN) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Neutral.
The score is held down primarily by weak financial durability (no revenue and ongoing cash burn) and bearish technicals (below major moving averages with negative MACD). Corporate updates provide some offset via reported program progress, while valuation metrics offer limited support due to a negative P/E and no dividend.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp. is a clinical-stage, oncology-focused biotechnology company developing innovative RNAi-based treatments for solid tumors driven by mutated KRAS, a leading oncogenic driver in human cancers. The company previously conducted a Phase 2a trial of its first-generation product, which showed a positive trend versus chemotherapy alone, and is now focused on advancing its lead candidate for locally advanced pancreatic cancer.
Average Trading Volume: 40,042
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.23M
Learn more about SLXN stock on TipRanks’ Stock Analysis page.